Epstein-Barr virus vaccine by 2032?
RégulationOne-OffSanté et médecineChineEuropeCriminalité et justice5a
Manifold MarketsSans KYCDonnées de résolution vérifiéesAssez bien calibréPrévision communautaire actuelleNon 65.3%
Prévisionnistes
5
Type de question
binary
Méthodologie
Play-money forecasting platform
Type de source
Prévision
Données du marché
Mis à jour il y a 10 heures
Obsolète26 oct. 25, 19:27 UTC31 déc. 31, 23:59 UTC
Tendances
Règles
Resolution: YES if, by 00:00 UTC on Jan 1, 2032, at least one prophylactic EBV vaccine (an active immunization product) has received regulatory authorization for use to prevent EBV infection or EBV‑associated disease (e.g., infectious mononucleosis, post‑transplant lymphoproliferative disease) from any of the following: FDA (U.S.), EMA (EU), MHRA (U.K.), PMDA (Japan), NMPA (China), Health Canada, TGA (Australia), or if the product appears on the WHO Emergency Use Listing (EUL) or the WHO prequalification (PQ) list for EBV prevention.
- What counts:
- Prophylactic EBV vaccines intended to prevent infection and/or clinical disease (e.g., Moderna’s mRNA‑1189; ferritin‑nanoparticle vaccines; other platforms).
- Approvals may be for specific age/risk groups or limited indications (e.g., prevention of mono in adolescents, or prevention of EBV disease in transplant recipients).
- Any formal regulatory approval/authorization meeting the above criteria counts.
- What doesn’t count:
